Meeting
2022 ASCO Annual Meeting
Differential prognostic effect of systemic inflammation in patients with NSCLC treated with immunotherapy or chemotherapy: A post hoc analysis of the phase III OAK trial.
Authors
Alessio Cortellini
Department of Surgery and Cancer, Imperial College London, London, United Kingdom
Alessio Cortellini , Biagio Ricciuti , Hossein Borghaei , Abdul Rafeh Naqash , Antonio D'Alessio , Claudia A.M. Fulgenzi , Alfredo Addeo , Giuseppe Luigi L. Banna , David J. James Pinato
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02008227
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9056)
DOI
10.1200/JCO.2022.40.16_suppl.9056
Abstract #
9056
Poster Bd #
44
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
First Author: Heng Tan
Poster
2021 ASCO Annual Meeting
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
First Author: Chul Kim
Poster
2020 ASCO Virtual Scientific Program
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Jia Luo